Vireo Growth (VREOF) Other Non-Current Liabilities (2021 - 2026)
Vireo Growth (VREOF) posted Other Non-Current Liabilities of $30.0 million for Q1 2026, up 1400.0% sequentially from $2.0 million in Q4 2025, and up 80376.42% YoY from N/an in Q1 2025.
Vireo Growth (VREOF) Other Non-Current Liabilities (2021 - 2026) Analysis & Trends
Vireo Growth has reported Other Non-Current Liabilities for 6 years, with the latest figure at $30.0 million in Q1 2026.
- Quarterly Other Non-Current Liabilities rose 80376.42% year-over-year to $30.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $30.0 million (up 80376.42% YoY) and the FY2025 annual result came in at $2.0 million, changed N/A from the prior year.
- Other Non-Current Liabilities climbed to $30.0 million in Q1 2026 per VREOF's latest filing, from $2.0 million in the prior quarter.
- Over five years, Other Non-Current Liabilities peaked at $30.0 million in Q1 2026 and troughed at $1613.0 in Q4 2022.
- A 5-year average of $4.1 million and a median of $216938.0 in 2024 frame the typical range for Other Non-Current Liabilities.
- The sharpest annual moves came in 2024 and 2026: Other Non-Current Liabilities retreated 8.66% in 2024, then jumped 80376.42% in 2026.
- Over 5 years, Other Non-Current Liabilities stood at $1613.0 in 2022, then jumped by 7454.0% to $121846.0 in 2023, then soared by 78.04% to $216938.0 in 2024, then surged by 821.92% to $2.0 million in 2025, then surged by 1400.0% to $30.0 million in 2026.
- According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $30.0 million, $2.0 million, and $1.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn |
| 3 | Zoetis | 31.79 Bn | 30.11 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.69 Bn | 22.89 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.25 Bn | 19.58 Bn | 683.80 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - |
| 10 | Vireo Growth | 487.39 Mn | 345.09 Mn | 95.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 30.00 Mn |
| Dec 31, 2025 | 2.00 Mn |
| Sep 30, 2025 | 1.10 Mn |
| Jun 30, 2025 | 10.63 Mn |
| Mar 31, 2025 | 37,278.00 |
| Sep 30, 2024 | 216,938.00 |
| Jun 30, 2024 | 196,598.00 |
| Dec 31, 2023 | 121,846.00 |
| Sep 30, 2023 | 235,577.00 |
| Jun 30, 2023 | 215,237.00 |
| Dec 31, 2022 | 1,613.00 |
| Sep 30, 2021 | 3.08 Mn |
| Jun 30, 2021 | 3.71 Mn |
| Mar 31, 2021 | 5.24 Mn |